Stem cell therapy is a promising strategy to treat muscle diseases such as Duchenne muscular dystrophy (DMD). To avoid immune rejection of donor cells or donor-derived muscle, autologous cells, which have been genetically modified to express dystrophin, are preferable to cells derived from healthy donors. Restoration of full-length dystrophin (FL-dys) using viral vectors is extremely challenging, due to the limited packaging capacity of the vectors, but we have recently shown that either a foamy viral or lentiviral vector is able to package FL-dys open-reading frame and transduce myoblasts derived from a DMD patient. Differentiated myotubes derived from these transduced cells produced FL-dys. Here, we transplanted the foamy viral dystrophin-corrected DMD myoblasts intramuscularly into mdx nude mice, and showed that the transduced cells contributed to muscle regeneration, expressing FL-dys in nearly all the muscle fibers of donor origin. Furthermore, we showed that the restored FL-dys recruited members of the dystrophin-associated protein complex and neuronal nitric oxide synthase within donor-derived muscle fibers, evidence that the restored dystrophin protein is functional. Dystrophin-expressing donor-derived muscle fibers expressed lower levels of utrophin than host muscle fibers, providing additional evidence of functional improvement of donor-derived myofibers. This is the first in vivo evidence that foamy virus vector-transduced DMD myoblasts can contribute to muscle regeneration and mediate functional dystrophin restoration following their intramuscular transplantation, representing a promising therapeutic strategy for individual small muscles in DMD.
Get full access to this article
View all access options for this article.
References
1.
MendellJR, ShillingC, LeslieND, et al.Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol, 2012; 71:304–313.
2.
SaccoA, DoyonnasR, KraftP, et al.Self-renewal and expansion of single transplanted muscle stem cells. Nature, 2008; 456:502–506.
3.
CollinsCA, OlsenI, ZammitPS, et al.Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell, 2005; 122:289–301.
4.
MengJ, CounsellJR, RezaM, et al.Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy. Sci Rep, 2016; 6:19750.
5.
YoungCS, HicksMR, ErmolovaNV, et al.A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell, 2016; 18:533–540.
6.
AmoasiiL, LongC, LiH, et al.Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med, 2018; 10:eaat0240.
7.
BengtssonNE, HallJK, OdomGL, et al.Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun, 2017; 8:14454.
NowrouziA, DittrichM, KlankeC, et al.Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol, 2006; 87(Pt 5):1339–1347.
10.
TrobridgeGD, MillerDG, JacobsMA, et al.Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A, 2006; 103:1498–1503.
11.
TrobridgeGD, BeardBC, WuRA, et al.Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One, 2012; 7:e45173.
12.
CounsellJR, AsgarianZ, MengJ, et al.Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep, 2017; 7:79.
13.
SweeneyNP, MengJ, PattersonH, et al.Delivery of large transgene cassettes by foamy virus vector. Sci Rep, 2017; 7:8085.
14.
FosterH, SharpPS, AthanasopoulosT, et al.Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther, 2008; 16:1825–1832.
15.
InouyeS, Sahara-MiuraY, SatoJ, et al.Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. Protein Expr Purif, 2015; 109:47–54.
16.
AnsariAM, AhmedAK, MatsangosAE, et al.Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev, 2016; 12:553–559.
17.
SweeneyNP, ReganC, LiuJ, et al.Rapid and efficient stable gene transfer to mesenchymal stromal cells using a modified foamy virus vector. Mol Ther, 2016; 24:1227–1236.
18.
MengJ, ChunS, AsfahaniR, et al.Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice. Mol Ther, 2014; 22:1008–1017.
19.
EhrhardtJ, BrimahK, AdkinC, et al.Human muscle precursor cells give rise to functional satellite cells in vivo. Neuromuscul Disord, 2007; 17:631–638.
20.
Silva-BarbosaSD, Butler-BrowneGS, Di SantoJP, et al.Comparative analysis of genetically engineered immunodeficient mouse strains as recipients for human myoblast transplantation. Cell Transplant, 2005; 14:457–467.
21.
MengJ, BenczeM, AsfahaniR, et al.The effect of the muscle environment on the regenerative capacity of human skeletal muscle stem cells. Skelet Muscle, 2015; 5:11.
22.
IrintchevA, ZweyerM, WernigA. Impaired functional and structural recovery after muscle injury in dystrophic mdx mice. Neuromuscul Disord, 1997; 7:117–125.
23.
MuellerAL, BlochRJ. Skeletal muscle cell transplantation: models and methods. J Muscle Res Cell Motil, 2019Aug7 [Epub ahead of print]; DOI: 10.1007/s10974-019-09550-w.
24.
RozkalneA, AdkinC, MengJ, et al.Mouse regenerating myofibers detected as false-positive donor myofibers with anti-human spectrin. Hum Gene Ther, 2014; 25:73–81.
25.
NasimuzzamanM, LynnD, ErnstR, et al.Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. Mol Ther Methods Clin Dev, 2016; 3:16004.
26.
LorantJ, SauryC, SchlederC, et al.Skeletal muscle regenerative potential of human MuStem cells following transplantation into injured mice muscle. Mol Ther, 2018; 26:618–633.
27.
XuX, WilschutKJ, KouklisG, et al.Human satellite cell transplantation and regeneration from diverse skeletal muscles. Stem Cell Rep, 2015; 5:419–434.
28.
OhlendieckK, MatsumuraK, IonasescuVV, et al.Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology, 1993; 43:795–800.
29.
CirakS, FengL, AnthonyK, et al.Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther, 2012; 20:462–467.
30.
MolzaAE, MangatK, LeRE, et al.Structural basis of neuronal nitric-oxide synthase interaction with dystrophin repeats 16 and 17. J Biol Chem, 2015; 290:29531–29541.
31.
LaiY, ZhaoJ, YueY, et al.Alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci U S A, 2013; 110:525–530.
32.
AmentaAR, YilmazA, BogdanovichS, et al.Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A, 2011; 108:762–767.
33.
BanksGB, CombsAC, OdomGL, et al.Muscle structure influences utrophin expression in mdx mice. PLoS Genet, 2014; 10:e1004431.
34.
MessinaS, VitaGL. Clinical management of Duchenne muscular dystrophy: the state of the art. Neurol Sci, 2018; 39:1837–1845.
ReinigAM, MirzaeiS, BerlauDJ. Advances in the treatment of Duchenne muscular dystrophy: new and emerging pharmacotherapies. Pharmacotherapy, 2017; 37:492–499.
KaweckaK, TheodoulidesM, HasogluY, et al.Adeno-associated virus (AAV) mediated dystrophin gene transfer studies and exon skipping strategies for Duchenne muscular dystrophy (DMD). Curr Gene Ther, 2015; 15:395–415.
39.
KodippiliK, HakimCH, PanX, et al.Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther, 2018; 29:299–311.
40.
WangZ, KuhrCS, AllenJM, et al.Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther, 2007; 15:1160–1166.
41.
LeGC, ServaisL, MontusM, et al.Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun, 2017; 8:16105.
42.
BauerTRJr., TuschongLM, CalvoKR, et al.Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency. Mol Ther, 2013; 21:964–972.
43.
BrimahK, EhrhardtJ, MoulyV, et al.Human muscle precursor cell regeneration in the mouse host is enhanced by growth factors. Hum Gene Ther, 2004; 15:1109–1124.
44.
CooperRN, ThiessonD, FurlingD, et al.Extended amplification in vitro and replicative senescence: key factors implicated in the success of human myoblast transplantation. Hum Gene Ther, 2003; 14:1169–1179.
45.
BoldrinL, ZammitPS, MuntoniF, et al.Mature adult dystrophic mouse muscle environment does not impede efficient engrafted satellite cell regeneration and self-renewal. Stem Cells, 2009; 27:2478–2487.
46.
BlakeDJ, TinsleyJM, DaviesKE. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol, 1996; 6:37–47.
47.
GuiraudS, EdwardsB, BabbsA, et al.The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum Mol Genet, 2019; 28:2189–2200.
48.
PonsF, RobertA, MariniJF, et al.Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency?. J Neurol Sci, 1994; 122:162–170.
49.
WeirAP, MorganJE, DaviesKE. A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord, 2004; 14:19–23.
50.
FerrettiR, NetoHS, MarquesMJ. Expression of utrophin at dystrophin-deficient neuromuscular synapses of mdx mice: a study of protected and affected muscles. Anat Rec (Hoboken), 2011; 294:283–286.
51.
SharpPS, JeeH, WellsDJ. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther, 2011; 19:165–171.
52.
NeriM, TorelliS, BrownS, et al.Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord, 2007; 17:913–918.
53.
PhelpsSF, HauserMA, ColeNM, et al.Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet, 1995; 4:1251–1258.
54.
WellsDJ, WellsKE, AsanteEA, et al.Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet, 1995; 4:1245–1250.
55.
VitielloL, BassiN, CampagnoloP, et al.In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscul Disord, 2008; 18:597–605.
56.
WilliamsJH, SchrayRC, SirsiSR, et al.Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnol, 2008; 8:35.
57.
YinH, MoultonHM, SeowY, et al.Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet, 2008; 17:3909–3918.
58.
BlaveriK, HeslopL, YuDS, et al.Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. Dev Dyn, 1999; 216:244–256.
59.
Aartsma-RusA, MorganJ, LonkarP, et al.Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. J Neuromuscul Dis, 2019; 6:147–159.
60.
GodfreyC, MusesS, McCloreyG, et al.How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet, 2015; 24:4225–4237.
61.
WellsDJ. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?. J Muscle Res Cell Motil, 2019; 40:141–150.
62.
NasimuzzamanM, KimYS, WangYD, et al.High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells. Mol Ther Methods Clin Dev, 2014; 1:14020.
63.
GoodmanMA, ArumugamP, PillisDM, et al.Foamy virus vector carries a strong insulator in its long terminal repeat which reduces its genotoxic potential. J Virol, 2018; 92.
64.
DeyleDR, KhanIF, RenG, et al.Lack of genotoxicity due to foamy virus vector integration in human iPSCs. Gene Ther, 2013; 20:868–873.
65.
CossuG, PrevitaliSC, NapolitanoS, et al.Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol Med, 2015; 7:1513–1528.
66.
KinaliM, Arechavala-GomezaV, CirakS, et al.Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology, 2011; 76:346–353.
67.
MengJ, AdkinCF, XuSW, et al.Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. PLoS One, 2011; 6:e17454.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
